Iron Deficiency Anemia Management

Patient Assessment and Treatment Criteria

The American Gastroenterological Association recommends oral iron as the first-line treatment for mild iron deficiency anemia in patients whose disease is clinically inactive and who have not been previously intolerant to oral iron 1, 2
Patients with documented iron deficiency anemia who have an unsatisfactory response, intolerance, or contraindication to oral iron administration may be considered for intravenous iron therapy 1, 2
The patient's current improvement with oral iron supplementation, despite recent medical challenges, supports the continuation of this therapy 1, 2

The American Gastroenterological Association recommends intravenous iron only when patients do not tolerate oral iron, ferritin levels do not improve with a trial of oral iron, or the patient has a condition in which oral iron is not likely to be absorbed 1
Current guidelines recommend oral iron as effective treatment for patients with mild anemia whose disease is clinically inactive and who have not been previously intolerant to oral iron 2, 3

Continue oral iron supplementation as the patient is showing improvement and is compliant with this therapy 1, 2
Monitor hemoglobin and iron studies to ensure continued improvement 2, 3
Re-evaluate iron status in 4-8 weeks to assess response to continued oral iron therapy 2, 3

A 55-year-old female patient with documented iron deficiency anemia (IDA) and abnormal blood chemistry findings has declining iron parameters, including hemoglobin, serum iron, transferrin saturation, and ferritin, despite oral iron supplementation 4, 5

Intravenous iron therapy is medically necessary for patients with documented iron deficiency anemia and an unsatisfactory response to oral iron administration, as evidenced by transferrin saturation below 20% and declining iron parameters despite oral iron supplementation 4, 5

For patients with unsatisfactory response to oral iron, intravenous iron administration is recommended to rapidly correct iron deficiency and improve symptoms, with a proposed regimen of 300mg IV weekly for 3 weeks being appropriate for replenishing iron stores 4, 5

Intravenous iron is superior to oral iron in patients who show inadequate response to oral therapy, producing significantly greater hemoglobin responses 4, 5

Iron parameters should be monitored 4-8 weeks after the last infusion to assess response, with expected increases in hemoglobin concentrations within 1-2 weeks of treatment and a goal ferritin level of 50 ng/mL in the absence of inflammation 5

Constipation is a potential side effect of oral iron, not an absolute contraindication, according to the American Gastroenterological Association and the American Society of Hematology 6, 7
Alternate-day dosing, lower elemental iron doses, ferrous bisglycinate, and liquid formulations are alternative oral iron strategies that can minimize constipation risk, as recommended by the American Gastroenterological Association 6, 7

The American College of Gastroenterology recommends alternate-day dosing to reduce hepcidin elevation and improve absorption while decreasing GI side effects 7
The American Society of Hematology suggests using lower elemental iron doses, such as 25-50 mg daily, to reduce GI side effects 6
Ferrous bisglycinate or polysaccharide-iron complex can provide better GI tolerability, according to the American Gastroenterological Association 6
Liquid formulations can also be used to minimize constipation risk, as recommended by the American College of Gastroenterology 6

The American Society of Hematology recommends serum ferritin <30 ng/mL or transferrin saturation (TSAT) <20% for diagnosing iron deficiency anemia 8
TSAT <20% has high sensitivity for diagnosing absolute or functional iron deficiency 8
Goal ferritin is 50 ng/mL in the absence of inflammation 8

The American Society of Hematology emphasizes that ferritin and TSAT remain the best performing tests for diagnosing iron deficiency and guiding IV iron therapy 8
Ferumoxytol must be infused over at least 15 minutes to minimize infusion reactions 9
Ferumoxytol is superparamagnetic iron oxide that interferes with MRI interpretation for up to 6 months after administration 9, 10
Exercise caution with generic ferumoxytol, which showed double the incidence of infusion reactions compared to brand name 9

Baseline iron studies are necessary to confirm iron deficiency, determine appropriate iron dosing, monitor response to therapy, and avoid potential iron overload 8
Document any planned MRI needs in the next 6 months when considering ferumoxytol treatment 10